These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17105835)

  • 1. Comment: impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    Grau S; Mateu-de Antonio J; Marin-Casino M
    Ann Pharmacother; 2006 Dec; 40(12):2280; author reply 2280-1. PubMed ID: 17105835
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.
    Bounthavong M; Hsu DI; Okamoto MP
    Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
    Schürmann D; Sorensen SV; De Cock E; Duttagupta S; Resch A
    Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?
    Nathwani D
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii37-44. PubMed ID: 12730141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
    Patanwala AE; Erstad BL; Nix DE
    Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of linezolid in the treatment of complicated skin and soft tissue infections.
    Peppard WJ; Weigelt JA
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):357-66. PubMed ID: 16771613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility?
    Howden BP; Charles PG; Johnson PD; Ward PB; Grayson ML
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4816; author reply 4816-7. PubMed ID: 16251343
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
    McCollum M; Sorensen SV; Liu LZ
    Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
    Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
    J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of linezolid versus vancomycin in the treatment of methicillin-resistant Staphylococcus aureus discitis: a controlled animal model.
    Conaughty JM; Chen J; Martinez OV; Chiappetta G; Brookfield KF; Eismont FJ
    Spine (Phila Pa 1976); 2006 Oct; 31(22):E830-2. PubMed ID: 17047530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain.
    Hentschke M; Saager B; Horstkotte MA; Scherpe S; Wolters M; Kabisch H; Grosse R; Heisig P; Aepfelbacher M; Rohde H
    Infection; 2008 Feb; 36(1):85-7. PubMed ID: 18165857
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship of linezolid minimum inhibitory concentration and time to bacterial eradication in treatment for methicillin-resistant Staphylococcus aureus infection.
    Moise PA; Castro RS; Sul C; Forrest A; Sakoulas G
    Ann Pharmacother; 2008 Apr; 42(4):592-3. PubMed ID: 18349303
    [No Abstract]   [Full Text] [Related]  

  • 18. Linezolid use in sepsis due to methicillin-susceptible Staphylococcus aureus.
    De Gascun C; Rajan L; O'Neill E; Smyth EG
    J Antimicrob Chemother; 2006 Jan; 57(1):150-1. PubMed ID: 16244085
    [No Abstract]   [Full Text] [Related]  

  • 19. Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?
    Kalil AC; Puumala S; Stoner J
    Antimicrob Agents Chemother; 2006 May; 50(5):1910; author reply 1910-1. PubMed ID: 16641477
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstem R
    Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.